NCT02833610 2026-02-18
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
12 trialsNCT06374459 2026-02-09
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Washington University School of Medicine
Phase 1/2 Recruiting
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
NCT04549207 2025-11-28
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT04067726 2025-10-16
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04586660 2025-10-01
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Amgen
Phase 4 Active not recruiting
NCT06513624 2025-07-25
ETC-159-02
National University Hospital, Singapore
Phase 1 Recruiting
NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
NCT03958565 2025-05-21
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
University of Colorado, Denver
Recruiting
NCT04907539 2025-04-16
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Redx Pharma Ltd
Phase 2 Completed
NCT04711109 2025-04-02
BRCA-P
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting